{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-055007","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.448249+00:00","generated_at":"2026-06-03T04:40:45.665859+00:00","sec_items":["1.01","2.03","3.02","7.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"TriSalus Life Sciences secures up to $50M debt financing from OrbiMed; $25M funded at close","bullets":["$25M funded on April 30, 2024; up to $25M additional available in two tranches subject to revenue thresholds.","Loan matures April 2029; interest rate is SOFR plus 8.50% (floor 4% SOFR); initial 15 months may accrue up to 3.5% PIK interest.","Issued OrbiMed warrant to purchase 130,805 shares at $9.5562; also registration rights agreement filed.","Company expects cash runway through 2025, targeting break-even EBITDA for TriNav business in 2025.","Covenants require minimum unrestricted cash of $5M (before March 31, 2025) and $10M thereafter."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-055007","json":"https://secwatch.observer/filing/0001104659-24-055007.json","markdown":"https://secwatch.observer/filing/0001104659-24-055007.md","text":"https://secwatch.observer/filing/0001104659-24-055007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/tm2413063d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:40:45.665859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"177c2615bc98bab4e6ee1398dd8b4cbc5c641b6f","claim":"TriSalus Life Sciences, Inc. incurred credit facility of $25 million with OrbiMed Royalty & Credit Opportunities IV, LP at SOFR plus 8.50% maturing April 30, 2029.","evidence_excerpt":"On April 30, 2024, the Borrower borrowed the Initial Commitment Amount, resulting in gross proceeds to the Borrower of $25 million.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"credit facility"},{"label":"Principal","value":"$25 million"},{"label":"Counterparty","value":"OrbiMed Royalty & Credit Opportunities IV, LP"},{"label":"Rate","value":"SOFR plus 8.50%"},{"label":"Maturity","value":"April 30, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"98cd241ca1c50972951ff6e6ec31e02376478486","claim":"TriSalus Life Sciences, Inc. entered into Credit Agreement with OrbiMed Royalty & Credit Opportunities IV, LP valued at Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $ (effective 2024-04-30).","evidence_excerpt":"On April 30, 2024 (the “ Closing Date ”), TriSalus Life Sciences, Inc., a Delaware corporation (the “ Company ”) and TriSalus Operating Life Sciences, Inc., a Delaware corporation and wholly owned subsidiary of the Company (the “ Borrower ”) entered into a Credit Agreement (the “ Credit Agreement ”), by and between the Company, as parent, the Borrower, as borrower, OrbiMed Royalty & Credit Opportunities IV, LP, a Delaware limited partnership (the “ Initial Lender ”), as a lender, and each other lender that may from time to time become a party thereto (each, including the Initial Lender, and together with their affiliates, successors, transferees and assignees, the “ Lenders ”), and OrbiMed Royalty & Credit Opportunities IV, LP, as administrative agent for the Lenders (in such capacity, the “ Administrative Agent ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1826667/000110465924055007/0001104659-24-055007-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"OrbiMed Royalty & Credit Opportunities IV, LP"},{"label":"Value","value":"Up to $50 million senior secured credit facility, $25 million initial borrowing on April 30, 2024, $"},{"label":"Effective","value":"2024-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}